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The live-attenuated yellow fever (YF) vaccine virus, strain 17D-204, has long been known to consist of a heterologous
population of virions. Gould et al. (J. Gen. Virol. 70, 1889–1894 (1989)) previously demonstrated that variant viruses exhibiting
a YF wild-type-specific envelope (E) protein epitope are present at low frequency in the vaccine pool and were able to
isolate representative virus variants with and without this epitope, designated 17D(/wt) and 17D(0wt), respectively. These
variants were employed here in an investigation of YF virus pathogenesis in the mouse model. Both the 17D-204 parent
and the 17D(/wt) variant viruses were lethal for adult outbred mice by the intracerebral route of inoculation. However, the
17D(0wt) variant was significantly attenuated (18% mortality rate) and replicated to much lower titer in the brains of infected
mice. A single amino acid substitution in the envelope (E) protein at E-240 (Ala r Val) was identified as responsible for the
restricted replication of the 17D(0wt) variant in vivo. The 17D(/wt) variant has an additional second-site mutation, believed
to encode a reversion to the neurovirulence phenotype of the 17D-204 parent virus. The amino acid substitution in the E
protein at E-173 (Thr r Ile) of the 17D(/wt) variant which results in the appearance of the wild-type-specific epitope or
nucleotide changes in the 5* and 3* noncoding regions of the virus are proposed as a candidates. q 1997 Academic Press
Yellow fever (YF) virus is the prototype member of the that in acquiring the wild-type epitope recognized by
Flavivirus genus, family Flaviviridae. The 17D live-attenu- MAb 117, the E protein had lost some of the antigenic
ated virus vaccine against YF has been available for characteristics of the parental 17D-204-UK vaccine virus.
more than 60 years and two substrains, 17D-204 and In contrast, other variants from the same preparation of
17DD, are currently manufactured commercially (for a 17D-204-UK lacking the MAb 117 wild-type epitope, but
review see 1). It has been well established that each of with vaccine-specific epitopes (identified by MAbs 411
the 17D-204 vaccine viruses consists of a heterogeneous and 864), were attenuated in adult mice, producing no
population of variants differing in plaque morphology (2), more than 40% lethality. One of the latter variants, desig-
mouse virulence (2 – 4), oligonucleotide fingerprint pat- nated 17D(0wt), was shown to infect mice and induce
terns (5), and antigenicity (6–10). Using a YF wild-type- antibody, but was avirulent (9). Viral antigen was still
specific monoclonal antibody (MAb 117), which has been detectable in the brains of the surviving mice 4 weeks
demonstrated to react only with an envelope (E) protein postinoculation. The authors suggested that this was due
epitope on the surface of wild-type YF viruses, Gould et to the development of a persistent infection. In this study,
al. (9) were able to identify wild-type antigenic variants the information accumulated by Gould et al. (9) regarding
in several different 17D-204 vaccine pools. the pathogenesis of the 17D(/wt) and 17D(0wt) variant
One such antigenic variant, 17D(/wt), isolated by viruses in mice is expanded. In addition, the molecular
plaque-purification from the 17D-204 vaccine virus manu- determinants of the phenotypic properties of these vi-
factured in the United Kingdom (17D-204-UK) and shown ruses have been identified.
to have the epitope recognized by wild-type-specific MAb Examination of the 17D(0wt) and 17D(/wt) variants
117, was also found to possess the 17D-204 substrain- with a larger panel of vaccine and wild-type-specific E
specific epitope recognized by MAb 864, but was nega- protein reactive MAbs (11) showed that they had both
tive with YF vaccine-specific MAb 411. This suggests retained the YF vaccine-specific and 17D-specific epi-
topes recognized by MAbs H5 and H6, respectively.
Thus, as suggested previously by Sil et al. (11), YF1 Present address: Department of Microbiology and Immunology,
University of North Carolina at Chapel Hill, NC 27514. vaccine-specific MAbs 411 (6) and H5 (11) probably do
2 To whom correspondence and reprint requests should be ad- not recognize the same epitope. Neither of the variantsdressed at Department of Pathology, University of Texas Medical
were recognized by E protein-reactive wild-type-spe-Branch, Galveston, TX 77555-0605. Fax: 409-747-2415. E-mail: abarrett@
mspo5.med.utmb.edu. cific MAbs S17, S18, S24, or S56 (11). Thus, MAb 117
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defines a wild-type epitope distinct from those identi-
fied by Sil et al. (11).
The variant viruses were compared for mouse viru-
lence with their parent virus, 17D-204-UK, in outbred T0
mice (Olac, UK) (Table 1). 17D-204-UK vaccine virus was
found to be 100% lethal for mice by the intracerebral (i.c.)
route of inoculation. By comparison, the 17D(/wt) variant
was found to have reduced lethality (85% mortality rate)
and the 17D(0wt) variant was significantly attenuated
(18% mortality rate) using an inoculum of 104 PFU. Com-
parison of virus neurovirulence for other mouse strains
revealed that, while the 17D-204-UK parental virus was
lethal by i.c. inoculation for all strains tested, the
17D(0wt) variant virus exhibited a varied phenotype de-
pendent on the mouse strain ranging from a 90% mortality
rate in C57BL/6 mice to avirulence in Balb/c mice (Table
1). Consequently, the host genetic restriction to 17D(0wt)
infection cannot be explained simply on the basis of
MHC antigens as virulence differed in two mouse strains
expressing H-2d MHC antigens (Balb/C and DBA/2 mice)
(Table 1).
In studies performed in parallel with those described
above, virus-infected outbred NIH Swiss mice were sacri-
ficed and their brains were harvested at 2, 3, and 8 days
postinoculation for virus titration and histopathological
examination. A group of control mice were inoculated
with the 17D-204-UK virus and treated similarly. At early
time-points, 2 and 3 days postinoculation, the 17D-204-
UK parent virus was detected at titers ranging from 4.5
1 104 to 7.5 1 105 PFU/brain (Table 2). Eight days postin-
oculation these titers had increased to in excess of 6.8
1 105 PFU/brain and mice were showing clinical signs
of disease. In comparison, at 2 days postinoculation, the
17D(0wt) variant virus titers of three sampled mouse
brains ranged from 15 to 3.0 1 102 PFU/brain and were
detected in all three mice sampled. By 3 days postinocu-
lation infectious virus was detectable in only one mouse
of three at 1.0 1 104 PFU/brain (with a 15 PFU/brain limit
of detection). Eight days postinoculation similar results
were obtained: the brain of one mouse (exhibiting signs
of encephalitis) contained 1.6 1 103 PFU, while no infec-
tious virus was detectable by this assay (£15 PFU/brain)
in the brains of two more mice which appeared to be
healthy. Two and three days postinoculation, virus was
detectable in all mouse brains infected with the 17D(/wt)
variant virus at titers of 1.5 1 103 to 2.4 1 104 PFU/brain.
By 8 days postinoculation these titers had risen in excess
of 3.6 1 105 PFU/brain and all mice were displaying
clinical signs of encephalitis.
Routine hematoxylin and eosin staining of brain sec-
tions from mice infected with the 17D-204-UK parent
virus or with the 17D(0wt) variant virus revealed little
pathology 8 days postinoculation. In both cases some
meningeal, perivascular, and parenchymal inflamma-
tion were observed. In the 17D-204-UK-virus-infected
brain sections microglial nodules were also identified
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TABLE 2 in vivo without active replication, and therefore it seems
likely that either residual inoculum was being detectedInfectivity Titers in Virus-Infected Mouse Brain Homogenate
or a low-level latent infection had been established as
Viral RNA proposed for E2 mutants of Sindbis virus (12). The latter
Day Infectivity titer detectable by theory is supported by the observation of Gould et al.
Virus postinoculation (PFU/brain) RT-PCRa (9) that antigen was detectable 4 weeks postinfection,
although infectious virions were below the level of detec-7.5 1 105
tion.2 7.5 1 105
7.5 1 105 In those mice which had detectable virus, no reversion
6.0 1 104 to wild-type phenotype at E-240 was observed by RT-
17D-204-UK 3 4.5 1 104 PCR sequencing analysis. In order to locate the wild-
6.3 1 104
type-specific epitope recognized by MAb 117 in the pri-6.8 1 105 /
mary amino acid sequence, the nucleotide and deduced8 6.0 1 106 /
1.7 1 106 / amino acid sequences of the region encoding the E pro-
tein for the two variant viruses 17D(/wt) and 17D(0wt),15
their parent virus 17D-204-UK (13), and the wild-type2 3.0 1 102
3.0 1 102 Asibi virus (14) were compared (Table 3). The E protein
1.0 1 104 gene nucleotide and deduced amino acid sequence of
17D(0wt) 3 15 the 17D(0wt) variant virus was identical to its 17D-204-15
UK parent virus at all of the positions at which 17D-204-1.6 1 103 /
UK differs from Asibi virus. Additionally, the 17D(0wt)8 15 /
15 0 variant virus exhibited four nucleotide changes from both
the Asibi and 17D-204-UK viruses, one of which (nt-1692)1.5 1 103
was found to encode the substitution of a valine for an2 2.4 1 104
9.0 1 103 alanine residue at amino acid position 240 in the E pro-
7.5 1 103 tein (E-240). The three remaining nucleotide mutations
17D(/wt) 3 4.5 1 103 (nt-1507, nt-2023, and nt-2437) were silent. The E protein
2.0 1 104
gene sequence of the 17D(/wt) variant virus was identi-3.6 1 105
cal to that of the 17D(0wt) variant virus except for one8 2.0 1 106
5.3 1 105 nucleotide mutation from the 17D-204-UK and 17D(0wt)
viruses at nt-1491. This mutation encodes the substitu-
a RT-PCR results represent detection (/) or not (0) of envelope pro- tion of a threonine residue in the 17D-204-UK virus for
tein gene on Day 8 postinfection and performed as described by Wang
an isoleucine residue in the 17D(/wt) variant at positionet al. (26).
E-173. Comparison with the sequence of the Asibi virus
at this position reveals that this nucleotide and resulting
amino acid substitution represent a reversion to the wild-and, by immunohistochemical staining, viral antigen
was sporadically detected in microglial cells. In con- type. To further investigate the molecular basis of the
attenuation exhibited by the 17D(0wt) and 17D(/wt) vari-trast, no viral antigen was detected in mouse brain
infected with the 17D(0wt) variant virus. No evidence ants, the nucleotide sequence for the entire genome of
both variants was determined. Over the entire 10,862of demyelination was observed in any of the sections
by luxol blue staining. nucleotides of the genome, the 17D(0wt) variant was
shown to be identical to the 17D-204-France vaccineRT-PCR was performed on total RNA from mouse brain
homogenates to determine whether viral RNA persisted virus (15), except for the four nucleotide changes identi-
fied in the E protein gene and described above. Conse-in the brains of mice infected with the 17D(0wt) variant
virus after clearance of infectious virions to a level below quently, the alanine to valine substitution revealed in the
E protein of the 17D(0wt) variant at E-240 represents theplaque assay detection (8 days postinoculation). RT-PCR
was performed on the mouse brain homogenates using only amino acid mutation in the virus genome. Other than
the E protein changes described above, the genome ofprimers specific for a 1.3-kb region of the E protein gene.
As shown in Table 2, viral RNA could be detected in the 17D(/wt) variant differed from 17D(0wt) and 17D-204-
France by seven nucleotides; one in the 5* noncodingbrains of two of three 17D(0wt) virus-infected mouse
brains at 8 days postinoculation even though infectious region (5*NCR) at nt-92, two in the 3*NCR at nucleotides
10,367 and 10,455 (a change to the nucleotide found invirus was detectable in only one mouse. Therefore, it
appears that the 17D(0wt) variant virus was able to repli- wild-type Asibi virus), and five in the coding region, all
of which were silent (Table 3). Interestingly, four of thecate in mouse neural tissues, but that fatal encephalitis
did not necessarily ensue. There is no known mechanism silent changes were to the same nucleotide found in
wild-type Asibi virus.by which positive-strand viral RNA genomes can persist
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TABLE 3
Comparison of the E Protein Gene Sequence Differences between 17D-204 UK, 17D(0wt), and 17D(/wt) Viruses and Comparison
with Wild-Type Parental Strain Asibi (14)
Nucleotide Asibi 17D-204-UK 17D(0wt) 17D(/wt) Amino acid Substitution
92 A A A G — —
509 T T T C — —
1491 C T T C E-173 T to I
1507 T T C C — —
1692 C C T T E-240 A to V
2023 T T C C — —
2437 T T C C — —
4054 C T T C — —
4238 C C C T — —
4873 G G G T — —
5641 G A A G — —
6578 T C C T — —
10367 T C C T — —
10455 G G G A — —
Study of the 17D(/wt) and 17D(0wt) variants of the An amino acid substitution in the T-cell epitope may con-
tribute to the host genetic restriction observed in17D-204-UK vaccine virus has contributed to our knowl-
edge of the attenuation of wild-type YF viruses in two 17D(0wt) virus-infected mice.
The recreation of the wild-type-specific epitope onareas. First, the position of the wild-type-specific epitope
recognized by MAb 117 has been mapped to residue E- 17D(/wt) virus was demonstrated to involve a reversion
to the wild-type sequence of Asibi virus at position E-173 in the primary amino acid sequence. This is the first
wild-type-specific epitope to be localized on the YF virus 173. The threonine residue found at position E-173 in the
wild-type Asibi virus was also found to be conservedE protein. Second, the entire genomic sequence of the
significantly attenuated 17D(0wt) variant has been deter- among all other wild-type YF viruses sequenced to date
(26, 27). However, a threonine is not found at this positionmined and the attenuating mutation identified at E-240.
This is only the second flavivirus variant to be de- in other members of the flavivirus genus which have
been sequenced (28, 29). These observations are consis-scribed with a single-site amino acid substitution which
results in an attenuated mouse neurovirulence pheno- tent with the hypothesis that this region defines the YF
wild-type-specific MAb 117-defined E protein epitope.type. Sumiyoshi et al. (16) previously showed that muta-
tion of residue E-138 attenuated the mouse neuroviru- A TBE virus E protein epitope mapped at E-171 (corre-
sponding to E-170 in YF virus) (30) has been shown tolence of wild-type Japanese encephalitis virus. In com-
parison, previous studies have reported MAb-derived undergo acid pH-induced conformational changes which
were proposed to interfere directly with processes nec-antigenic variants with only reduced neuroinvasive
capabilities and no reduced neurovirulence (17 – 21). essary for membrane fusion (23). The corresponding
MAb escape variant virus exhibited a significantly lowerThe E-240 mutation maps to domain II of the E protein,
as defined by the three-dimensional structure of the cen- pH threshold for the induction of its fusion activity. The
single amino acid substitution at E-171 was speculatedtral european tick-borne encephalitis (TBE) virus E pro-
tein ectodomain determined by Rey et al. (22). Domain II to strengthen the oligomeric E protein structure and thus
lower the pH requirement for the structural rearrange-undergoes a pH-dependent conformational change (23),
consistent with its speculated role in endocytic fusion ments necessary for membrane fusion (31). Further ex-
amination of the 17D(/wt) variant is necessary to revealevents (24). The substitution at E-240 may alter the E
protein structure and resistance to low pH-induced con- whether or not the equivalent epitope on the YF virus E
protein is also involved in acid pH-induced membraneformational changes. However, further investigation
would be necessary to determine the role of any such fusion events. However, the replacement of isoleucine
with threonine at this position increases the hydrophil-conformational changes in the attenuation of the virus
for neurovirulence in mice. E-240 also occurs within a icity of this region, possibly inducing conformational
changes and exposing the wild-type epitope on the sur-dominant IAb-restricted T-helper cell epitope defined by
Mathews et al. (25) for Murray Valley encephalitis virus. face of the E protein.
Finally, the 17D(0wt) variant was attenuated forThe highly conserved architecture of the flavivirus E pro-
teins allows us to speculate that the equivalent region mouse neurovirulence and found to be identical in se-
quence to other 17D-204 viruses over the whole ge-of the YF virus E protein will also form a T-cell epitope.
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